search
Back to results

LEVANT 2 Continuation Registry of the Lutonix® Drug Coated Balloon (DCB)

Primary Purpose

Peripheral Artery Disease

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Lutonix Drug Coated Balloon
Sponsored by
C. R. Bard
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Peripheral Artery Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Clinical Inclusion Criteria:

  1. Male or non-pregnant female ≥18 years of age;
  2. Rutherford Clinical Category 2-4;
  3. Patient is willing to provide informed consent, is geographically stable and comply with the required follow up visits, testing schedule and medication regimen;

    Angiographic Lesion Inclusion Criteria:

  4. Length ≤15 cm;
  5. Up to two focal lesions or segments within the designated 15 cm length of vessel may be treated (e.g. two discrete segments, separated by several cm, but both falling within a composite length of <15 cm);
  6. ≥70% stenosis by visual estimate;
  7. Lesion location starts ≥1 cm below the common femoral bifurcation and terminates distally ≤2 cm below the tibial plateau AND ≥1 cm above the origin of the TP trunk;
  8. de novo lesion(s) or non-stented restenotic lesion(s) >90 days from prior angioplasty procedure;
  9. Lesion is located at least 3 cm from any stent, if target vessel was previously stented;
  10. Target vessel diameter between ≥4 and ≤6 mm and able to be treated with available device size matrix;
  11. Successful, uncomplicated (without use of a crossing device) antegrade wire crossing of lesion;
  12. A patent inflow artery free from significant lesion (≥50% stenosis) as confirmed by angiography (treatment of target lesion acceptable after successful treatment of inflow artery lesions); NOTE: Successful inflow artery treatment is defined as attainment of residual diameter stenosis ≤30% without death or major vascular complication.
  13. At least one patent native outflow artery to the ankle, free from significant (≥50%) stenosis as confirmed by angiography that has not previously been revascularized (treatment of outflow disease is NOT permitted during the index procedure);
  14. Contralateral limb lesion(s) cannot be treated within 2 weeks before and/or planned 30 days after the protocol treatment in order to avoid confounding complications;
  15. No other prior vascular interventions within 2 weeks before and/or planned 30 days after the protocol treatment.

Exclusion Criteria:

Patients will be excluded if ANY of the following conditions apply:

  1. Pregnant or planning on becoming pregnant or men intending to father children;
  2. Life expectancy of <5 years;
  3. Patient is currently participating in an investigational drug or other device study or previously enrolled in this study; NOTE: Enrollment in another clinical trial during the follow up period is not allowed.
  4. History of hemorrhagic stroke within 3 months;
  5. Previous or planned surgical or interventional procedure within 2 weeks before or within 30 days after the index procedure;
  6. History of MI, thrombolysis or angina within 2 weeks of enrollment;
  7. Rutherford Class 0, 1, 5 or 6;
  8. Renal failure or chronic kidney disease with MDRD GFR ≤30 ml/min per 1.73 m2 (or serum creatinine ≥2.5 mg/L within 30 days of index procedure or treated with dialysis);
  9. Prior vascular surgery of the index limb, with the exception of remote common femoral patch angioplasty separated by at least 2 cm from the target lesion;
  10. Inability to take required study medications or allergy to contrast that cannot be adequately managed with pre- and post-procedure medication;
  11. Anticipated use of IIb/IIIa inhibitor prior to randomization;
  12. Ipsilateral retrograde access;
  13. Composite lesion length is >15 cm or there is no normal proximal arterial segment in which duplex flow velocity can be measured;
  14. Significant inflow disease. Successful treatment of inflow disease allowed prior to target lesion treatment;
  15. Known inadequate distal outflow (>50 % stenosis of distal popliteal and/or all three tibial vessels), or planned future treatment of vascular disease distal to the target lesion;
  16. Sudden symptom onset, acute vessel occlusion, or acute or sub-acute thrombus in target vessel;
  17. Severe calcification that renders the lesion un-dilatable;
  18. Use of adjunctive treatment modalities (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloon, etc.).

Sites / Locations

  • Good Samaritan Hospital
  • North County Radiology Medial Group Inc.
  • St. Joseph's Hospital
  • University of California Davis
  • Medical Center of the Rockies
  • Yale New Haven Hospital
  • Washington Cardiology Center
  • Heart and Vascular Institute
  • Interventional Cardiolgists of Gainesville
  • Munroe Regional Medical Center
  • Cardiovascular Associates
  • Advocate Christ Medical Center
  • Edward Heart / Midwest Research Foundation
  • St. John's Hosptial
  • Allen County Cardiology
  • St. Vincent Heart Center of Indianapolis
  • Promise Regional Medical Center
  • St. Francis Heart & Vascular Center
  • Massachusetts Genearl Hospital
  • Detroit Medical Center
  • St. John's Hospital
  • Michigan Heart
  • Mercy Hosptial
  • Forrest General Hospital
  • Deborah Heart and Lung Center
  • Our Lady of Lourdes Medical Center
  • Mount Sinai Medical Center
  • Columbia Universtiy Medical Center
  • Wake Heart and Vascular
  • Christ Hospital / The Lindner Clinical Trial Center
  • University Hospitals Cleveland Medical Center
  • Cleveland Clinic
  • Mid Ohio Cardiology and Vascular Consultants
  • Jobst Vascular Institute
  • Univesrity of Toledo Medical Center
  • Greenville Memorial Hospital
  • Wellmont Cardiology Services
  • East Tennessee Heart Consultants
  • Austin Heart P.A.
  • Medical University of Graz
  • Klinikum Klagenfurt
  • OLV Ziekenhuis
  • Imelda Ziekenhuis
  • Flanders Medical Research Program
  • Hospital Oost-Limburg
  • Ghent University Hospital
  • Herz-Zentrum
  • Jewish Hospital
  • Universitätsklinikum Carl Gustav Carus
  • Diakonissenanstalt zu Flensburg
  • Hamburg University Cardiovascular Center
  • University Clinical Center Heidelberg
  • Herz-Und Gefasszentrum
  • Practice for Interventional Radiology
  • Westpfalz Clinic
  • University Leipzig
  • University Magdeburg
  • Universtiy Clinic Muenster
  • University of Munich
  • Ernst von Bergham Clinic
  • University of Tübingen
  • University Hospital
  • Canton Hospital Lucerne
  • University Hospital, Zurich

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Lutonix Drug Coated Balloon

Arm Description

Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter

Outcomes

Primary Outcome Measures

Number of Unanticipated Device- or Drug- Related Adverse Events Through 60 Months Post Index Procedure

Secondary Outcome Measures

Number of Patients With Freedom From All-Cause Perioperative (≤ 30 Day) Death and Freedom From Index Limb Amputation, Index Limb Re-Intervention, and Index-Limb-Related Death at 1, 6, 12, 24, 36, 48, and 60 Months Post Index Procedure
Composite of freedom from all-cause perioperative (≤ 30 day) death and freedom from the following at 1, 6, 12, 24, 36, 48, and 60 months: index limb amputation, index limb re-intervention, and index-limb-related death.
Number of Acute Device Success at Time of Index Procedure
In certain procedures, more than one device was use resulting in a higher number of devices (894) than participants (657) for this endpoint.
Number of Participants With Freedom From All-cause Death, Index Limb Amputation Above the Ankle and Target Vessel Revascularization (TVR) at 30 Days Post Index Procedure
This VIVA Safety Endpoint is defined as Freedom at 30 days from all-cause death, index limb amputation above the ankle and target vessel revascularization (TVR).
Number of Participants With Freedom From Index Limb Amputation, Index Limb Re-Intervention, and Index-Limb-Related Death at 1, 6, 12, 24, 36, 48, and 60 Months Post Index Procedure (PPI)
Number of Participants With Technical and Procedural Success
Number of Participants With Primary Patency of the Target at 6, 12, and 24 Months Post Index Procedure
Primary patency is defined as freedom from target lesion restenosis by core lab adjudication (DUS ≥ 2.5) and target lesion revascularization (TLR).
Change From Baseline of Index-limb Resting Ankle Brachial Index (ABI) at 6, 12, and 24 Months Post Index Procedure
Presented is a summary of the Mean change in resting Ankle Brachial Index (ABI) from baseline through 24 months post index procedure. The ABI is defined as a ratio of ankle to brachial (upper arm) artery systolic blood pressure and aims at determining how well the blood is flowing in the legs. A lower ABI number suggests more Peripheral Arterial Disease.
Number of Participants With Freedom From Target Lesion Revascularization (TLR) at 1, 6, 12, and 24 Months Post Index Procedure
Improvement From Baseline in Rutherford Classification (Index Limb) at 6, 12, and 24 Months Post Index Procedure
The endpoint summarizes the change in index-limb Rutherford Classification of participants from baseline through 24 months. Data is presented as shift from baseline Rutherford Classification data using the following categories: 1) Improvement, 2) Same, and 3) Worsened.
Number of Participants With Primary Patency Based on Alternative Peak Systolic Velocity Ratio (PSVR) Thresholds at 6, 12, and 24 Months Post Index Procedure
Alternative Primary and Secondary Patency based on alternative definitions of Duplex Ultrasonography (DUS) Peak Systolic Velocity Ratio (PSVR) <2.0 and <3.0 Duplex Ultrasonography (DUS) Clinical Patency (DUS Peak Systolic Velocity Ratio (PSVR) <2.5 without prior Clinically Driven TLR)

Full Information

First Posted
June 19, 2012
Last Updated
March 31, 2020
Sponsor
C. R. Bard
search

1. Study Identification

Unique Protocol Identification Number
NCT01628159
Brief Title
LEVANT 2 Continuation Registry of the Lutonix® Drug Coated Balloon (DCB)
Official Title
A Prospective, Multicenter, LEVANT 2 Continuation Registry of the Moxy™ Drug Coated Balloon for Treatment of Femoropopliteal Arteries
Study Type
Interventional

2. Study Status

Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
June 2012 (undefined)
Primary Completion Date
September 2018 (Actual)
Study Completion Date
December 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
C. R. Bard

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of the study is to collect additional safety and efficacy information on the Lutonix (formerly Moxy) Drug Coated Balloon for treatment of stenosis or occlusion of the femoral and popliteal arteries.
Detailed Description
The purpose of the study is to collect additional safety and efficacy information on the Lutonix (formerly Moxy) Drug Coated Balloon for treatment of stenosis or occlusion of the femoral and popliteal arteries through 5 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Artery Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
657 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Lutonix Drug Coated Balloon
Arm Type
Experimental
Arm Description
Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
Intervention Type
Device
Intervention Name(s)
Lutonix Drug Coated Balloon
Other Intervention Name(s)
Moxy Drug Coated Balloon
Intervention Description
balloon angioplasty with a drug coated balloon
Primary Outcome Measure Information:
Title
Number of Unanticipated Device- or Drug- Related Adverse Events Through 60 Months Post Index Procedure
Time Frame
60 months Post Index Procedure
Secondary Outcome Measure Information:
Title
Number of Patients With Freedom From All-Cause Perioperative (≤ 30 Day) Death and Freedom From Index Limb Amputation, Index Limb Re-Intervention, and Index-Limb-Related Death at 1, 6, 12, 24, 36, 48, and 60 Months Post Index Procedure
Description
Composite of freedom from all-cause perioperative (≤ 30 day) death and freedom from the following at 1, 6, 12, 24, 36, 48, and 60 months: index limb amputation, index limb re-intervention, and index-limb-related death.
Time Frame
1, 6, 12, 24, 36, 48 and 60 months Post Index Procedure
Title
Number of Acute Device Success at Time of Index Procedure
Description
In certain procedures, more than one device was use resulting in a higher number of devices (894) than participants (657) for this endpoint.
Time Frame
At time of Index Procedure
Title
Number of Participants With Freedom From All-cause Death, Index Limb Amputation Above the Ankle and Target Vessel Revascularization (TVR) at 30 Days Post Index Procedure
Description
This VIVA Safety Endpoint is defined as Freedom at 30 days from all-cause death, index limb amputation above the ankle and target vessel revascularization (TVR).
Time Frame
30 days post index procedure
Title
Number of Participants With Freedom From Index Limb Amputation, Index Limb Re-Intervention, and Index-Limb-Related Death at 1, 6, 12, 24, 36, 48, and 60 Months Post Index Procedure (PPI)
Time Frame
1, 6, 12, 24, 36, 48, and 60 months post index procedure
Title
Number of Participants With Technical and Procedural Success
Time Frame
At time of index procedure
Title
Number of Participants With Primary Patency of the Target at 6, 12, and 24 Months Post Index Procedure
Description
Primary patency is defined as freedom from target lesion restenosis by core lab adjudication (DUS ≥ 2.5) and target lesion revascularization (TLR).
Time Frame
6, 12, and 24 months post index procedure
Title
Change From Baseline of Index-limb Resting Ankle Brachial Index (ABI) at 6, 12, and 24 Months Post Index Procedure
Description
Presented is a summary of the Mean change in resting Ankle Brachial Index (ABI) from baseline through 24 months post index procedure. The ABI is defined as a ratio of ankle to brachial (upper arm) artery systolic blood pressure and aims at determining how well the blood is flowing in the legs. A lower ABI number suggests more Peripheral Arterial Disease.
Time Frame
6, 12, and 24 months post index procedure
Title
Number of Participants With Freedom From Target Lesion Revascularization (TLR) at 1, 6, 12, and 24 Months Post Index Procedure
Time Frame
1, 6, 12, and 24 months post index procedure
Title
Improvement From Baseline in Rutherford Classification (Index Limb) at 6, 12, and 24 Months Post Index Procedure
Description
The endpoint summarizes the change in index-limb Rutherford Classification of participants from baseline through 24 months. Data is presented as shift from baseline Rutherford Classification data using the following categories: 1) Improvement, 2) Same, and 3) Worsened.
Time Frame
6, 12, and 24 months post index procedure
Title
Number of Participants With Primary Patency Based on Alternative Peak Systolic Velocity Ratio (PSVR) Thresholds at 6, 12, and 24 Months Post Index Procedure
Description
Alternative Primary and Secondary Patency based on alternative definitions of Duplex Ultrasonography (DUS) Peak Systolic Velocity Ratio (PSVR) <2.0 and <3.0 Duplex Ultrasonography (DUS) Clinical Patency (DUS Peak Systolic Velocity Ratio (PSVR) <2.5 without prior Clinically Driven TLR)
Time Frame
6, 12, and 24 months post index procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Clinical Inclusion Criteria: Male or non-pregnant female ≥18 years of age; Rutherford Clinical Category 2-4; Patient is willing to provide informed consent, is geographically stable and comply with the required follow up visits, testing schedule and medication regimen; Angiographic Lesion Inclusion Criteria: Length ≤15 cm; Up to two focal lesions or segments within the designated 15 cm length of vessel may be treated (e.g. two discrete segments, separated by several cm, but both falling within a composite length of <15 cm); ≥70% stenosis by visual estimate; Lesion location starts ≥1 cm below the common femoral bifurcation and terminates distally ≤2 cm below the tibial plateau AND ≥1 cm above the origin of the TP trunk; de novo lesion(s) or non-stented restenotic lesion(s) >90 days from prior angioplasty procedure; Lesion is located at least 3 cm from any stent, if target vessel was previously stented; Target vessel diameter between ≥4 and ≤6 mm and able to be treated with available device size matrix; Successful, uncomplicated (without use of a crossing device) antegrade wire crossing of lesion; A patent inflow artery free from significant lesion (≥50% stenosis) as confirmed by angiography (treatment of target lesion acceptable after successful treatment of inflow artery lesions); NOTE: Successful inflow artery treatment is defined as attainment of residual diameter stenosis ≤30% without death or major vascular complication. At least one patent native outflow artery to the ankle, free from significant (≥50%) stenosis as confirmed by angiography that has not previously been revascularized (treatment of outflow disease is NOT permitted during the index procedure); Contralateral limb lesion(s) cannot be treated within 2 weeks before and/or planned 30 days after the protocol treatment in order to avoid confounding complications; No other prior vascular interventions within 2 weeks before and/or planned 30 days after the protocol treatment. Exclusion Criteria: Patients will be excluded if ANY of the following conditions apply: Pregnant or planning on becoming pregnant or men intending to father children; Life expectancy of <5 years; Patient is currently participating in an investigational drug or other device study or previously enrolled in this study; NOTE: Enrollment in another clinical trial during the follow up period is not allowed. History of hemorrhagic stroke within 3 months; Previous or planned surgical or interventional procedure within 2 weeks before or within 30 days after the index procedure; History of MI, thrombolysis or angina within 2 weeks of enrollment; Rutherford Class 0, 1, 5 or 6; Renal failure or chronic kidney disease with MDRD GFR ≤30 ml/min per 1.73 m2 (or serum creatinine ≥2.5 mg/L within 30 days of index procedure or treated with dialysis); Prior vascular surgery of the index limb, with the exception of remote common femoral patch angioplasty separated by at least 2 cm from the target lesion; Inability to take required study medications or allergy to contrast that cannot be adequately managed with pre- and post-procedure medication; Anticipated use of IIb/IIIa inhibitor prior to randomization; Ipsilateral retrograde access; Composite lesion length is >15 cm or there is no normal proximal arterial segment in which duplex flow velocity can be measured; Significant inflow disease. Successful treatment of inflow disease allowed prior to target lesion treatment; Known inadequate distal outflow (>50 % stenosis of distal popliteal and/or all three tibial vessels), or planned future treatment of vascular disease distal to the target lesion; Sudden symptom onset, acute vessel occlusion, or acute or sub-acute thrombus in target vessel; Severe calcification that renders the lesion un-dilatable; Use of adjunctive treatment modalities (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloon, etc.).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kenneth Rosenfield, MD
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Prof. Dierk Scheinert, MD
Organizational Affiliation
University Leipzig
Official's Role
Principal Investigator
Facility Information:
Facility Name
Good Samaritan Hospital
City
Los Angeles
State/Province
California
ZIP/Postal Code
90017
Country
United States
Facility Name
North County Radiology Medial Group Inc.
City
Oceanside
State/Province
California
ZIP/Postal Code
92056
Country
United States
Facility Name
St. Joseph's Hospital
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Facility Name
University of California Davis
City
Sacramento
State/Province
California
ZIP/Postal Code
95817
Country
United States
Facility Name
Medical Center of the Rockies
City
Loveland
State/Province
Colorado
ZIP/Postal Code
80538
Country
United States
Facility Name
Yale New Haven Hospital
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06510
Country
United States
Facility Name
Washington Cardiology Center
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20010
Country
United States
Facility Name
Heart and Vascular Institute
City
Clearwater
State/Province
Florida
ZIP/Postal Code
33756
Country
United States
Facility Name
Interventional Cardiolgists of Gainesville
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32605
Country
United States
Facility Name
Munroe Regional Medical Center
City
Ocala
State/Province
Florida
ZIP/Postal Code
34471
Country
United States
Facility Name
Cardiovascular Associates
City
Elk Grove Village
State/Province
Illinois
ZIP/Postal Code
60007
Country
United States
Facility Name
Advocate Christ Medical Center
City
Oak Lawn
State/Province
Illinois
ZIP/Postal Code
60453
Country
United States
Facility Name
Edward Heart / Midwest Research Foundation
City
Oakbrook Terrace
State/Province
Illinois
ZIP/Postal Code
60181
Country
United States
Facility Name
St. John's Hosptial
City
Springfield
State/Province
Illinois
ZIP/Postal Code
62710
Country
United States
Facility Name
Allen County Cardiology
City
Fort Wayne
State/Province
Indiana
ZIP/Postal Code
46802
Country
United States
Facility Name
St. Vincent Heart Center of Indianapolis
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46290
Country
United States
Facility Name
Promise Regional Medical Center
City
Hutchinson
State/Province
Kansas
ZIP/Postal Code
67502
Country
United States
Facility Name
St. Francis Heart & Vascular Center
City
Topeka
State/Province
Kansas
ZIP/Postal Code
66606
Country
United States
Facility Name
Massachusetts Genearl Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Name
Detroit Medical Center
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Facility Name
St. John's Hospital
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48236
Country
United States
Facility Name
Michigan Heart
City
Ypsilanti
State/Province
Michigan
ZIP/Postal Code
48197
Country
United States
Facility Name
Mercy Hosptial
City
Coon Rapids
State/Province
Minnesota
ZIP/Postal Code
55433
Country
United States
Facility Name
Forrest General Hospital
City
Hattiesburg
State/Province
Mississippi
ZIP/Postal Code
39401
Country
United States
Facility Name
Deborah Heart and Lung Center
City
Browns Mills
State/Province
New Jersey
ZIP/Postal Code
08015
Country
United States
Facility Name
Our Lady of Lourdes Medical Center
City
Cherry Hill
State/Province
New Jersey
ZIP/Postal Code
08034
Country
United States
Facility Name
Mount Sinai Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Facility Name
Columbia Universtiy Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Facility Name
Wake Heart and Vascular
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27610
Country
United States
Facility Name
Christ Hospital / The Lindner Clinical Trial Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Facility Name
University Hospitals Cleveland Medical Center
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Facility Name
Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Facility Name
Mid Ohio Cardiology and Vascular Consultants
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43214
Country
United States
Facility Name
Jobst Vascular Institute
City
Toledo
State/Province
Ohio
ZIP/Postal Code
43606
Country
United States
Facility Name
Univesrity of Toledo Medical Center
City
Toledo
State/Province
Ohio
ZIP/Postal Code
43614
Country
United States
Facility Name
Greenville Memorial Hospital
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29615
Country
United States
Facility Name
Wellmont Cardiology Services
City
Kingsport
State/Province
Tennessee
ZIP/Postal Code
37660
Country
United States
Facility Name
East Tennessee Heart Consultants
City
Knoxville
State/Province
Tennessee
ZIP/Postal Code
37934
Country
United States
Facility Name
Austin Heart P.A.
City
Austin
State/Province
Texas
ZIP/Postal Code
78705
Country
United States
Facility Name
Medical University of Graz
City
Graz
ZIP/Postal Code
A-8036
Country
Austria
Facility Name
Klinikum Klagenfurt
City
Klagenfurt
Country
Austria
Facility Name
OLV Ziekenhuis
City
Aalst
Country
Belgium
Facility Name
Imelda Ziekenhuis
City
Bonheiden
Country
Belgium
Facility Name
Flanders Medical Research Program
City
Dendermonde
Country
Belgium
Facility Name
Hospital Oost-Limburg
City
Genk
Country
Belgium
Facility Name
Ghent University Hospital
City
Ghent
Country
Belgium
Facility Name
Herz-Zentrum
City
Bad Krozingen
Country
Germany
Facility Name
Jewish Hospital
City
Berlin
Country
Germany
Facility Name
Universitätsklinikum Carl Gustav Carus
City
Dresden
Country
Germany
Facility Name
Diakonissenanstalt zu Flensburg
City
Flensburg
Country
Germany
Facility Name
Hamburg University Cardiovascular Center
City
Hamburg
Country
Germany
Facility Name
University Clinical Center Heidelberg
City
Heidelberg
Country
Germany
Facility Name
Herz-Und Gefasszentrum
City
Immenstadt
Country
Germany
Facility Name
Practice for Interventional Radiology
City
Kaiserslautern
Country
Germany
Facility Name
Westpfalz Clinic
City
Kusen
Country
Germany
Facility Name
University Leipzig
City
Leipzig
Country
Germany
Facility Name
University Magdeburg
City
Magdeburg
Country
Germany
Facility Name
Universtiy Clinic Muenster
City
Muenster
Country
Germany
Facility Name
University of Munich
City
Munich
Country
Germany
Facility Name
Ernst von Bergham Clinic
City
Potstdam
Country
Germany
Facility Name
University of Tübingen
City
Tübingen
Country
Germany
Facility Name
University Hospital
City
Bern
Country
Switzerland
Facility Name
Canton Hospital Lucerne
City
Lucerne
Country
Switzerland
Facility Name
University Hospital, Zurich
City
Zurich
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Not at this time.
Citations:
PubMed Identifier
31575518
Citation
Ouriel K, Adelman MA, Rosenfield K, Scheinert D, Brodmann M, Pena C, Geraghty P, Lee A, White R, Clair DG. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease. JACC Cardiovasc Interv. 2019 Dec 23;12(24):2515-2524. doi: 10.1016/j.jcin.2019.08.025. Epub 2019 Sep 28.
Results Reference
derived

Learn more about this trial

LEVANT 2 Continuation Registry of the Lutonix® Drug Coated Balloon (DCB)

We'll reach out to this number within 24 hrs